Recombinant Lysyl Endopeptidase Market Demand and Optimizing Protein Analysis

Recombinant Lysyl Endopeptidase Market Size, Companies and Shares

The recombinant lysyl endopeptidase market was estimated at US$ 38 million in 2023 and is projected to grow to US$ 67.06 million by 2034, rising at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2034.

Key Takeaways

• North America dominated the global recombinant lysyl endopeptidase market in 2024.
• Asia Pacific is expected to be the fastest-growing during the forecast period.
• By type, the powder segment dominated the market in 2024.
• By application type, the protein analysis segment dominated the market in 2024.

Recombinant Lysyl Endopeptidase Market: Enzyme Engineering

Recombinant lysyl endopeptidase is an enzyme that hydrolyzes amide and peptide ester bonds at the carboxylic side of lysine and S-aminoethyl cysteine residues. Lysyl endopeptidase is mainly derived from three microorganisms, Achromobacter, Lysobacterium, and Pseudomonas aeruginosa. The natural form of the enzyme is not widely used due to its low yield, complex purification process, and long production cycle. However, the recombinant form resolves the issues, resulting in increased yield with high purification.

Recombinant lysyl endopeptidase is commonly used in proteomics, peptide sequencing, insulin preparation, identification of phosphorylated peptides, disulfide bond analysis, N-glycan analysis, and detection of glycated hemoglobin. The growing research and development and increasing R&D investments drive the market. The research areas like proteomics, genetic engineering, and personalized medicine increase the demand for recombinant lysyl endopeptidase. Additionally, the increasing cases of diabetes increase the demand for insulin, potentiating the market.

Recombinant Lysyl Endopeptidase Market Trends

• In September 2024, Sino Biological, a leading recombinant protein production company, announced a strategic partnership with BioGeometry, a pioneer in generative AI for protein design. The partnership will enhance Sino Biological’s advanced protein expression and wet lab capabilities with BioGeometry’s generative AI protein design and optimization platform.
• The Chinese Government recently launched the π-HuB Consortium to invest in the development of new proteomic technologies, with a particular focus on single-cell proteomic and protein sequencing technologies. The project was made to develop computational models and tools for disease risk assessment, diagnosis, and treatment guidance.

Growth Factors

• Increasing occurrences of diabetes: The rising occurrences of diabetes are increasing the demand for the use of recombinant lysyl endopeptidase in the development of insulin, which is driving the market growth.
• Increasing research and development: Due to the increasing applications of the use of recombinant lysyl endopeptidase, the interest in the development of new treatment strategies is increasing.
• New developments: Various new approaches are being developed with the help of recombinant lysyl endopeptidase in protein structure analysis, sequencing, and biomarker discovery.

Market Dynamics

Increasing Demand for Proteomics

Proteomics is the complete study of the function, interactions, composition, and structures of proteins to understand an organism's nature. Proteomics can aid in identifying different proteins and targets involved in a disease. It is also essential in novel drug discovery and identification of disease biomarkers. Additionally, proteomics gives ideas about protein-protein interactions, which are useful in cell signaling cascades and gene regulatory networks. Recombinant lysyl endopeptidase is an essential enzyme for proteomics research. The increasing incidences of chronic disorders, demand for novel drug discovery and development, diagnostics, and early identification of the disease potentiates the need for proteomics. This further leads to an increase in demand for recombinant lysyl endopeptidase.

High Cost Hinder the Recombinant Lysyl Endopeptidase Market

The high cost of recombinant lysyl endopeptidase is a major restraint of the market. The average cost of the recombinant protein is around $350 to $500 per 20 μG. This limits the affordability of many laboratories and research institutions in lower- and middle-income countries.

Regional Growth Analysis

State-of-the-Art R&D Facilities Dominated North America

North America dominated the recombinant lysyl endopeptidase market in 2023. The state-of-the-art research & development facilities, favorable capital investment, increasing awareness for proteomics and genetic engineering, and the presence of key players drive the market. Countries like the US and Canada are at the forefront of promoting the market. The US and Canadian government bodies like the National Institute of Standards and Technology and the National Cancer Institute support several initiatives regarding proteomics research.

The approval of novel drugs is higher in the region than in the rest of the world. The US FDA approved 37 new drugs in 2022 and 55 new drugs in 2023. The increasing investments in the biotechnology sector favor the growth of the market. Additionally, the increasing incidences of type 1 diabetes promote market growth. In 2022, the US reported the highest number of type 1 diabetes cases globally. Canada was also ranked among the top ten countries with the highest number of type 1 diabetes cases, accounting for approximately 300,000 cases.

Increasing Incidences of Diabetes to Promote Asia-Pacific

Asia-Pacific is estimated to grow fastest in the recombinant lysyl endopeptidase market during the forecast period. The increasing incidences of chronic disorders, growing research & development activities, increasing number of patents, and rising awareness for proteomics, genetic engineering, and personalized medicines drive the market. India and China were ranked second and fourth, respectively, with the highest number of type 1 diabetes cases globally in 2022. According to the Indian Council of Medical Research (ICMR) report, around 95,600 children below the age of 14 years suffered from type 1 diabetes in 2022.

Europe Poised for Strong Growth in Recombinant Lysyl Endopeptidase Market

Europe is expected to grow significantly in the recombinant lysyl endopeptidase market during the forecast period. The increasing diseases is increasing the demand for new effective treatment options. This, in turn, increases the use of recombinant lysyl endopeptidase. Thus, it promotes the market growth.

UK Market Trends

Due to growing diseases, the industries in the UK are focusing on the development of new treatment approaches with the use of recombinant lysyl endopeptidase. Moreover, the research conducted is also rising. This, in turn, is further supported by the investments provided by the government.

Germany Market Trends

Germany consists of various industries and institutes that are developing multiple treatment options to treat diabetes. At the same time, the use of recombinant lysyl endopeptidase is also rising in the development of these treatment approaches. This further leads to rising collaborations between the industries as well as institutes.

Segmental Insights

By type, the powder segment held a dominant presence in the market in 2023. The recombinant lysyl endopeptidase powder is highly preferred as it is stable and lightweight. It can be easily stored and transported, requiring less cost. Also, the requirement of minute quantity favors the use of powder form of the recombinant protein.

By application, the protein analysis segment held the largest share of the market in 2023. Recombinant lysyl endopeptidase is widely used in proteomics and protein identification. The increasing incidences of chronic disorders demand early detection and treatment of disease, necessitating a deeper understanding of disease prognosis. The increasing demand for proteomics and novel drug discovery research promotes segment growth.

Recent Developments in the Recombinant Lysyl Endopeptidase Market

• In October 2023, researchers from the East China University of Science and Technology developed a novel recombinant expression and purification strategy for lysyl endopeptidase. The novel process resulted in high yield and good activity of the recombinant protein.
• In August 2024, researchers from Fudan University, China, assessed the regulation of microthrombosis in type 2 diabetes mellitus patients by analyzing platelets using 4D label-free proteomics and bioinformatics. Recombinant lysyl endopeptidase was used in sample platelet preparation. The results showed that lysosome can be a promising therapeutic target for antithrombotic treatment in type 2 diabetes mellitus.

Top Companies in the Recombinant Lysyl Endopeptidase Market

• Abcam
• ACRO Biosystems
• Alpha Laboratories
• Biomall
• Biomatik
• Cusabio
• Cosmo Bio USA, Inc.
• Gene Biocon
• MyBioSource
• OriGene
• Promega Corporation
• SERVA Electrophoresis GmBH
• Sigma-Aldrich
• Sino Biological
• VWR, Inc.

Segments Covered in the Report

By Type

• Powder
• Liquid

By Application

• Protein Analysis
• Insulin Manufacturing
• Others

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait